A 73‑year‑old patient with hypertension was switched to losartan potassium 25 mg daily, has persistent elevated blood pressure readings and painful lower‑extremity edema, and has hypokalemia (serum potassium 3.2 mmol/L) after stopping triamterene‑hydrochlorothiazide and starting potassium chloride. What is the appropriate management plan?

Management of Uncontrolled Hypertension with Edema and Hypokalemia in a 73-Year-Old Patient

The patient should immediately restart a low-dose loop diuretic (furosemide 20-40 mg daily) to address the symptomatic edema and uncontrolled hypertension, while continuing potassium supplementation and increasing the losartan dose to 100 mg daily for adequate blood pressure control. 1

Immediate Management Priorities

Address the Acute Problem: Edema and Uncontrolled Blood Pressure

The patient's painful lower extremity edema and persistently elevated blood pressure (readings 151-179/73-98 mmHg) require urgent intervention. The abrupt discontinuation of triamterene-HCTZ without replacing the diuretic component has caused fluid retention and inadequate blood pressure control. 1

• Restart diuretic therapy immediately with a loop diuretic (furosemide 20-40 mg once daily) rather than thiazide-based therapy, as loop diuretics are preferred in patients with heart failure or significant fluid retention 1
• Loop diuretics are the preferred agents for most patients with heart failure and can adequately control fluid retention while providing antihypertensive effects 1
• The patient's self-administration of triamterene demonstrates the severity of her symptoms and the urgent need for proper diuretic management 2

Optimize Losartan Dosing

Losartan 25 mg is a subtherapeutic dose for this patient. 3, 4

• Studies demonstrate that losartan 50-100 mg produces clinically important blood pressure reductions, while 10-25 mg doses are not consistently different from placebo at 24 hours after dosing 3
• Increase losartan to 50 mg daily initially, with titration to 100 mg daily if blood pressure remains uncontrolled 3, 4
• In patients with severe hypertension, losartan can be titrated up to 100 mg once daily as needed 4
• The higher dose will also help prevent hypokalemia, as high-dose losartan (150 mg) has been shown to decrease the risk of hypokalemia compared to low-dose therapy 5

Hypokalemia Management

Continue and Monitor Potassium Supplementation

Continue potassium chloride 40 mEq daily (20 mEq twice daily with meals) as prescribed. 1

• Recheck serum potassium in 1 week as planned 1
• Do not restart potassium-sparing diuretics (triamterene) at this time while the patient is on ACE inhibitor/ARB therapy and potassium supplementation, as this combination increases hyperkalemia risk 1
• Guidelines recommend using potassium-sparing diuretics only if hypokalemia persists despite ACE inhibitor/ARB therapy and diuretics, with careful monitoring every 5-7 days until values stabilize 1

Important Caveat on Combination Therapy

Once potassium levels normalize and stabilize, if the patient requires both diuretic therapy and continued potassium management, consider switching to a fixed-dose combination of losartan/hydrochlorothiazide rather than adding back triamterene. 6

• Fixed-dose combination therapy with losartan/HCTZ is associated with lower risk of hypokalemia compared to monotherapy (adjusted OR 0.32) 7
• This combination is safe and effective in elderly patients, including those ≥75 years 6
• The combination provides superior blood pressure control compared to high-dose ARB monotherapy 6

Blood Pressure Target and Monitoring

The target blood pressure for this patient should be 120-129/<80 mmHg, provided treatment is well tolerated. 1

• Current 2024 ESC guidelines recommend targeting systolic BP of 120-129 mmHg in most adults to reduce cardiovascular risk 1
• For patients with heart failure and hypertension, treatment should include behavioral modification (sodium restriction) and pharmacological therapy with diuretics, ACE inhibitors/ARBs, and beta-blockers 1
• Schedule follow-up evaluation within 1 week to assess response to treatment adjustments, adherence, and potassium levels 1

Medication Reconciliation and Patient Education

Critical Safety Issue

The patient must be instructed NOT to take her old triamterene-HCTZ pills. 2

• Taking triamterene while on potassium supplementation and losartan significantly increases hyperkalemia risk 1
• Explain that the new regimen addresses both her blood pressure and potassium levels more safely 1

Monitoring Plan

• Blood pressure: Daily home monitoring with follow-up in 1 week 1
• Serum potassium and creatinine: Recheck in 1 week, then every 5-7 days until stable 1
• Assess for resolution of edema and improvement in symptoms at 1-week follow-up 1

Why This Approach is Superior

The combination of loop diuretic, optimized-dose losartan, and potassium supplementation addresses all three problems simultaneously: uncontrolled hypertension, symptomatic edema, and hypokalemia. 1, 5

• Loop diuretics provide more effective volume control than thiazides in patients with significant fluid retention 1
• Higher-dose losartan (50-100 mg) provides adequate blood pressure control and reduces hypokalemia risk 5, 3
• This approach avoids the dangerous combination of potassium-sparing diuretics with RAS inhibitors and potassium supplementation 1
• Studies show that hypokalemia has a stronger association with poor outcomes than hyperkalemia in heart failure patients on ARB therapy 5